Atossa Therapeutics (ATOS) Price & Analysis

Compare

2,457 Followers

ATOS Stock Chart & Stats

$0.76

>-$0.01(-0.49%)

At close: Jan 08 4:00 PM EST

$0.76

>-$0.01(-0.49%)

Day’s Range― - ―

52-Week Range$0.55 - $1.36

Previous CloseN/A

Volume314.80K

Average Volume (3M)1.16M

Market Cap

$109.55M

Enterprise Value$49.24M

Total Cash (Recent Filing)$51.84M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta2.01

Next Earnings

Apr 01, 2026

EPS Estimate

-0.07

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.07

Shares Outstanding129,171,420

10 Day Avg. Volume1,949,046

30 Day Avg. Volume1,157,820

Financial Highlights & Ratios

PEG Ratio0.28

Price to Book (P/B)1.66

Price to Sales (P/S)0.00

P/FCF Ratio-5.65

Enterprise Value/Market Cap0.45

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-6.16K

Enterprise Value/Ebitda-1.53

Forecast

1Y Price Target

$6.25

Price Target Upside722.37% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Financial PositionAtossa should have a clean capital structure that includes $57.8M in cash reported at the end of 2Q25 (runway into 2027) and no debt.

Market PotentialThe need in breast cancer treatment and/or risk management is substantial, the market opportunities are very large, and the data has been positive across the spectrum of indications.

Regulatory AdvancementsThe decision to go for accelerated development and possible NDA filing for the risk-reduction settings is a significant positive, in our view, and representative of the potential for endoxifen.

Bears Say

Atossa Therapeutics News

Atossa Therapeutics reports Q3 EPS (7c), consensus (7c)

“We continue to make meaningful and measurable progress across our (Z)-endoxifen development strategy in oncology,” stated Steven Quay,...

8d ago

ATOS

Atossa Therapeutics: Strategic Advancements in Breast Cancer Treatment Drive Buy Rating

Atossa Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCarthy from...

7d ago

ATOS

Atossa Therapeutics Reports Increased Q3 Losses Amid R&D Focus

Atossa Therapeutics, Inc. ( ($ATOS) ) has released its Q3 earnings. Here is a breakdown of the information...

8d ago

ATOS

Atossa Therapeutics: Advancements in Z-endoxifen Development and Strategic Leadership Enhancements Drive Buy Rating

Atossa Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Emily Bodnar from...

8d ago

ATOS

Atossa Therapeutics Advances Breast Cancer Treatment with (Z)-Endoxifen Study

Atossa Therapeutics, Inc. (($ATOS)) announced an update on their ongoing clinical study. Atossa Therapeutics, Inc. is conducting a...

24d ago

ATOS

Atossa Therapeutics Appoints New Chief Financial Officer

Atossa Therapeutics ( ($ATOS) ) has shared an update. On October 14, 2025, Atossa Therapeutics announced the appointment...

1M ago

ATOS

Atossa Therapeutics appoints Mark Daniel as CFO

Atossa Therapeutics (ATOS) appointed Mark Daniel as CFO. Daniel is a senior finance leader with more than 25...

1M ago

ATOS

Atossa Therapeutics advances global patent strategy for Z-Endoxifen

Atossa Therapeutics (ATOS) announces key progress in its global intellectual-property strategy for Z-endoxifen, including the issuance of an...

1M ago

ATOS

Atossa Therapeutics management to meet virtually with Craig-Hallum

Virtual Meeting to be held on October 10 hosted by Craig-Hallum. Published first on TheFly – the ultimate...

1M ago

ATOS

Strategic Adjustments and Promising Data Bolster Atossa Therapeutics’ Buy Rating

Analyst Emily Bodnar of H.C. Wainwright maintained a Buy rating on Atossa Therapeutics, retaining the price target of...

1M ago

ATOS

Promising Potential of Atossa Therapeutics’ Endoxifen in Metastatic Breast Cancer Treatment

Analyst Jason McCarthy from Maxim Group maintained a Buy rating on Atossa Therapeutics and keeping the price target...

2M ago

ATOS

Atossa Therapeutics Releases Updated Corporate Presentation

Atossa Therapeutics ( ($ATOS) ) has provided an announcement. On September 26, 2025, Atossa Therapeutics, Inc. released an...

2M ago

ATOS

Atossa Therapeutics: Strategic Advancements and Strong Financial Position Signal Promising Future

Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Atossa Therapeutics, retaining the price target of...

2M ago

ATOS

Atossa Therapeutics appoints CORE IR for investor relations

Atossa Therapeutics (ATOS) announces it has appointed CORE IR, a strategic investor relations, public relations, and corporate advisory...

2M ago

ATOS

ATOS FAQ

What was Atossa Therapeutics’s price range in the past 12 months?

Atossa Therapeutics lowest stock price was $0.55 and its highest was $1.36 in the past 12 months.

What is Atossa Therapeutics’s market cap?

Atossa Therapeutics’s market cap is $109.55M.

When is Atossa Therapeutics’s upcoming earnings report date?

Atossa Therapeutics’s upcoming earnings report date is Apr 01, 2026 which is in 132 days.

How were Atossa Therapeutics’s earnings last quarter?

Atossa Therapeutics released its earnings results on Nov 12, 2025. The company reported -$0.07 earnings per share for the quarter, missing the consensus estimate of -$0.065 by -$0.005.

Is Atossa Therapeutics overvalued?

According to Wall Street analysts Atossa Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Atossa Therapeutics pay dividends?

Atossa Therapeutics does not currently pay dividends.

What is Atossa Therapeutics’s EPS estimate?

Atossa Therapeutics’s EPS estimate is -0.07.

How many shares outstanding does Atossa Therapeutics have?

Atossa Therapeutics has 129,171,420 shares outstanding.

What happened to Atossa Therapeutics’s price movement after its last earnings report?

Atossa Therapeutics reported an EPS of -$0.07 in its last earnings report, missing expectations of -$0.065. Following the earnings report the stock price went down -2.41%.

Which hedge fund is a major shareholder of Atossa Therapeutics?

Currently, no hedge funds are holding shares in ATOS

Atossa Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-48.89%

Trailing 12-Months

Asset Growth

-24.86%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Atossa Therapeutics

Atossa Therapeutics, Inc. (ATOS) is a clinical-stage biopharmaceutical company focused on developing innovative medicines in the areas of oncology and infectious diseases, with an emphasis on breast cancer and COVID-19. The company's leading programs include potential treatments for breast cancer and COVID-19-related conditions, leveraging a combination of proprietary technologies and strategic partnerships to advance its clinical pipeline.

Atossa Therapeutics (ATOS) Earnings & Revenues

Historic Earnings Reports

ATOS Stock 12 Month Forecast

Average Price Target

$6.25

▲(722.37% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","-1":"-$1","1.25":"$1.25","3.5":"$3.5","5.75":"$5.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":7.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$7.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$6.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1.25,3.5,5.75,8],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.89,1.4176923076923078,1.9453846153846155,2.473076923076923,3.000769230769231,3.5284615384615385,4.056153846153846,4.583846153846154,5.111538461538461,5.639230769230768,6.1669230769230765,6.694615384615385,7.222307692307692,{"y":7.75,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.89,1.3023076923076924,1.7146153846153847,2.126923076923077,2.539230769230769,2.951538461538462,3.363846153846154,3.7761538461538464,4.188461538461539,4.600769230769231,5.013076923076923,5.4253846153846155,5.837692307692308,{"y":6.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.89,1.1292307692307693,1.3684615384615384,1.6076923076923078,1.846923076923077,2.086153846153846,2.3253846153846154,2.5646153846153847,2.8038461538461537,3.043076923076923,3.2823076923076924,3.5215384615384617,3.7607692307692306,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.46,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.42,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.27,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.94,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.76,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.65,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.84,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.87,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.82,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.82,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.76,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.92,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.89,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >